Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin in Persistent Atrial Fibrillation
NCT05252624Phase 3Unknown
- Sponsor
- Beijing An Zhen Hospital
- Start
- Sep 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Henagliflozin with Placebo (2 arms). Primary endpoint: Change in left atrial minimal volume index at 6 months. Status: unknown.
02
Drugs
henagliflozin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT05252624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05252624.